ADMA BIOLOGICS, INC. 8-K

What Happened

• On January 12, 2026, ADMA Biologics, Inc. announced preliminary, unaudited full-year 2025 revenue and provided a business update via a press release. The filing (Form 8-K Item 2.02) notes these results are preliminary, have not been audited, and may change after the completion of the company’s accounting and annual audit procedures.
• The company also furnished a corporate presentation for potential investors and analysts (Item 7.01), available on ADMA’s investor website. The press release is provided as Exhibit 99.1 and the presentation as Exhibit 99.2 to the 8-K.

Key Details

• Filing date: January 12, 2026 (Form 8-K).
• Announcement: preliminary, unaudited full-year 2025 revenue (no audited figures provided in the 8-K).
• Exhibits furnished: Exhibit 99.1 (press release) and Exhibit 99.2 (January 2026 corporate presentation).
• Status: Results are subject to adjustment pending completion of accounting and the annual audit; additional disclosures will be required for a complete view of financial position as of December 31, 2025.

Why It Matters

• This gives investors an early look at ADMA’s 2025 revenue performance, which can affect near-term sentiment and trading. However, because the figures are preliminary and unaudited, they should be treated as provisional — the final audited results (and related disclosures in the annual report/10-K) are needed for a definitive assessment of earnings and financial condition. The furnished corporate presentation may provide additional context about business trends and strategy but does not replace audited financial statements.